Tirzepatide for Obesity and Chronic Kidney Disease

(TREASURE-CKD Trial)

This trial explores whether the drug tirzepatide (also known as Mounjaro, Zepbound, or LY3298176) can benefit individuals with obesity and chronic kidney disease. Researchers aim to determine if tirzepatide can improve kidney health, regardless of type 2 diabetes status. Participants will receive either tirzepatide or a placebo (a substance with no active medicine) for comparison. Suitable candidates have a BMI of 27 or more and a diagnosis of chronic kidney disease. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group.

The trial does not specify if you need to stop taking your current medications. However, you must be on a stable dose of ACE or ARB medications for chronic kidney disease or hypertension unless you have low blood pressure.

Studies have shown that tirzepatide is generally safe and well-tolerated. Research indicates that it may lower the risk of major heart and kidney problems. In previous studies, people taking tirzepatide experienced fewer serious health issues compared to those not taking it. Another study found that tirzepatide maintained a consistent safety record, with no unexpected side effects. Most side effects were mild, such as nausea or diarrhea, and often improved over time. Overall, the evidence suggests that tirzepatide is safe for use.¹²³⁴⁵

Researchers are excited about tirzepatide because it offers a new approach to managing obesity and chronic kidney disease. Unlike most treatments that focus solely on reducing appetite or inhibiting fat absorption, tirzepatide is a dual-action drug that mimics the effects of two hormones, GLP-1 and GIP, which are involved in blood sugar regulation and appetite control. This novel mechanism not only aids in weight loss but also holds promise for improving kidney function. Additionally, tirzepatide is administered via a simple subcutaneous injection, making it a convenient option for patients.

Research shows that tirzepatide, which participants in this trial may receive, can greatly reduce serious kidney and heart problems in people with obesity, especially those with type 2 diabetes. Studies have found that tirzepatide lowers the risk of death from any cause and reduces serious kidney issues. It also helps people with obesity lose weight and maintain that weight loss over time. These findings suggest that tirzepatide could be a promising option for managing chronic kidney disease in people with obesity.¹²⁵⁶⁷